SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccineFull results will be submitted for publication later this year

Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine

The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine

Novavax says its COVID vaccine produces fewer, milder reactions than Pfizer version

On average, workers who received Novavax had 1.7 systemic symptoms, compared with 2.8 in Pfizer recipients.